ArticleAnnals of medicine and surgery (2012)2019
Quantitative assessment of Ki67 expression in correlation with various breast cancer characteristics and survival rate; cross sectional study.
Article in Annals of medicine and surgery (2012), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Lipocalin-2 in Triple-Negative Breast Cancer: A Review of Its Pathophysiological Role in the Metastatic Cascade.International journal of molecular sciences · 2025Review
- Article
- The Role of Ki-67 in HR+/HER2- Breast Cancer: A Real-World Study of 956 Patients.Breast cancer (Dove Medical Press) · 2024Article
- Investigation of breast cancer microstructure and microvasculature from time-dependent DWI and CEST in correlation with histological biomarkers.Scientific reports · 2022Article
- Mammary duct ectasia in adult females; risk factors for the disease, a case control study.Annals of medicine and surgery (2012) · 2021Article
- Vitamin D level and endogenous DNA damage in patients with cancers in Duhok city, KRG-Iraq.Annals of medicine and surgery (2012) · 2020Article
- A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study.Annals of medicine and surgery (2012) · 2020Article
- Evaluation of mastalgia in patients presented to the breast clinic in Duhok city, Iraq: Cross sectional study.Annals of medicine and surgery (2012) · 2020Article
- The Inhibitory Effect of Carboplatin Injection on Human Neuroblastoma SK-N-SH.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKi-67 is a cellular proliferative index that has variable expression during cell cycle. The absence of Ki-67 in the quiescent tissues and its expression in the proliferating cells had linked its possible role in the proliferative capacity of the tissues. MATERIALS AND
methodsThis retrospective study included 314 patients with breast cancer who underwent various types of breast surgeries. Analyzed was done to find any possible correlation between the level of Ki67 and various patient and tumor characteristics and the survival rates.
resultsThe mean age was 48.73 years, the overall survival was 30.77 months, 90.8% of the patients were alive and 8.3% died from breast cancer. In 85.67% no recurrence was reported and 5% had local and axillary recurrences, the commonest sites of metastases were bones and the vertebrae (2.2% and 1.9%) respectively. The mean size of the tumor was 34.39 mm and the mean number of the positive axillary nodes was 4. The expression of Ki67 was around 5-10% in the majority of patients, the mean expression was 28.54%. There was significant correlation between the level of Ki67 and the histopathological grade of the tumor, p value 0.003, and there was no significant correlation with other variables. There was no relation between the overall survival and the Ki67 level.
conclusionKi67 is correlated with the grade of the tumor, and is not a predictor for the survival of breast cancer patients. It may predict aggressive behavior of the tumor and higher histopathological grades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.